Study of E7389 Liposomal Formulation in Subjects With Solid Tumor

    Not Recruiting
  • participants needed
  • sponsor
    Eisai Co., Ltd.
Updated on 18 June 2021
Inquiry Service
Primary Contact
Eisai Trial Site 2 (7.2 mi away) Contact
+5 other location
measurable disease
breast cancer
endocrine therapy
lung cancer
colony stimulating factor
neutrophil count
hormone therapy
blood transfusion
cancer treatment
solid tumor
platelet transfusion
kidney function test


The maximum tolerated dose (MTD) of E7389 liposomal formulation (E7389-LF) will be determined in the dose escalation part. Safety, pharmacokinetics (PK) and efficacy will be assessed using treatment regimen evaluated in dose escalation part in participants with breast cancer in the expansion part 1 and in participants with adenoid cystic carcinoma (ACC), gastric cancer (GC), esophageal cancer (EGC), and small cell lung cancer (SCLC) in the expansion part 2, 3, 4, and 5.

Condition Solid Tumor
Treatment E7389-LF
Clinical Study IdentifierNCT03207672
SponsorEisai Co., Ltd.
Last Modified on18 June 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note